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The potential of induced pluripotent stem (iPS) cells is enormous, but many obstacles remain 
before their medical and pharmaceutical applications can be fully realized.In 2006, we showed that mouse embry-
onic and adult fibroblasts acquire prop-
erties similar to those of embryonic 
stem (ES) cells after retrovirally intro-
ducing genes encoding four transcrip-
tion factors, namely Oct3/4, Sox2, Klf4, 
and c-Myc (Takahashi and Yamanaka, 
2006). We called these cells induced 
pluripotent stem (iPS) cells. The first 
generation iPS cells were similar to 
ES cells in morphology, proliferation, 
the expression of some ES cell marker 
genes, and the formation of teratomas. 
However, these iPS cells had a different 
global gene expression pattern from ES 
cells and failed to produce adult chi-
meric mice. In 2007, germline transmis-
sion was achieved with mouse iPS cells 
(Meissner et al., 2007; Okita et al., 2007; 
Wernig et al., 2007), and iPS cells were 
generated from human fibroblasts (Park 
et al., 2008b; Takahashi et al., 2007; Yu 
et al., 2007).
Then four groups generated iPS cells 
from patients with various neurodegen-
erative diseases—amyotrophic lateral 
sclerosis (ALS) (Dimos et al., 2008), spi-
nal muscular atrophy (SMA) (Ebert et al., 
2009), and Parkinson’s disease (Soldner 
et al., 2009)—and a variety of genetic 
diseases with either Mendelian or com-
plex inheritance (Park et al., 2008a). 
Importantly, the pathology of SMA has 
been recapitulated in motor neurons 
derived from patient-specific iPS cells 
(Ebert et al., 2009). In addition, iPS cells 
have been generated from both mon-
key (Liu et al., 2008) and rat (Liao et al., 
2009). Here, I summarize the potential 
applications of iPS cell technology for 
drug discovery and medicine and the 
challenges to be surmounted to make 
this a reality (Figure 1). I believe that one 
of the most important challenges is to 
develop simple yet sensitive and reliable methods to evaluate the effectiveness 
and safety of the myriad iPS cell clones 
and subclones generated by many dif-
ferent technologies.
Long-Term Applications and 
 Challenges
Various types of somatic cells derived 
from pluripotent stem cells could be used 
in regenerative medicine to repair tissues 
damaged through disease or injury. The 
therapeutic effects of human ES cell-
derived progeny have been reported 
in animal models of spinal cord injury 
(Keirstead et al., 2005), retinal disease 
(Lamba et al., 2009), and Parkinson’s 
disease (Yang et al., 2008). In January 
2009, the US Food and Drug Administra-
tion (FDA) approved the first clinical trial 
for using human ES cells to treat patients 
with spinal cord injury.CeThe iPS cell technology potentially 
could overcome two important obsta-
cles associated with human ES cells: 
immune rejection after transplantation 
and ethical concerns regarding the use 
of human embryos. However, the clini-
cal application of iPS cells also faces 
many obstacles, some shared with ES 
cells and others that are unique. The first 
common obstacle is teratoma formation 
(Li et al., 2008). Even a small number of 
undifferentiated cells can result in the 
formation of teratomas (germ cell tumors 
comprising several cell types), so a key 
goal is to induce differentiation of human 
ES cells or iPS cells into the required cell 
type while leaving few undifferentiated 
cells behind. Should terminally differenti-
ated cells or tissue stem/progenitor cells 
derived from iPS cells be used and how 
should they be transplanted?Figure 1. Applications of iPS Cell Technology
Patient-derived iPS cells can produce various somatic cells with the same genetic information as the 
patient. These cells could be used to construct disease models and to screen effective and safe drugs, 
as well as to treat patients through cell transplantation therapy. Banking of iPS cells of various HLA types 
would be useful for regenerative medicine.ll 137, April 3, 2009 ©2009 Elsevier Inc. 13
Figure 2. Old and New Ways to Generate iPS Cells
Regardless of methodology, direct reprogramming could result in fully reprogrammed iPS cells that are 
comparable to ES cells, partially reprogrammed iPS cells that can self-renew and differentiate into certain 
cell lineages, or aberrantly reprogrammed cells that self-renew but are refractory to differentiation.There are also unique hurdles to over-
come before iPS cells can be used in 
the clinic, primarily related to the forced 
reprogramming of somatic cells. We 
still do not know for each iPS cell clone 
whether nuclear reprogramming is com-
plete (Figure 2). Aberrant reprogram-
ming may result in an impaired ability to 
differentiate and may increase the risk 
of immature teratoma formation after 
directed differentiation. Notably, abnor-
mal expression of a single gene (such 
as Nat1, Grb2, Apc, or Nanog) renders 
ES cells refractory to differentiation 
(Yamanaka et al., 2000). Thus, incom-
plete reprogramming of somatic cells 
to iPS cells could result in impaired dif-
ferentiation of iPS cells into the required 
cell type.
Another key issue is the presence 
of transgenes in iPS cells. Most iPS 
cells are generated by transduction of 
somatic cells with retroviruses or lenti-
viruses carrying transgenes, which are 
integrated into the host cell genome. 
Transgenes are largely silenced in iPS 
cells, but the reactivation of such trans-
genes (especially the transgene encod-
ing c-Myc) could lead to tumorigenesis 
(Okita et al., 2007). Leaky expression of 
these transgenes may also inhibit com-
plete iPS cell differentiation and matu-
ration, leading to a greater risk of imma-
ture teratoma formation.
Short-Term Applications and 
Challenges
A short-term goal is to use iPS cell tech-
nology for drug or toxicology screens 
in vitro and for creating disease models 14 Cell 137, April 3, 2009 ©2009 Elsevier Incin culture (Figure 1). Liver cells (hepato-
cytes) generated from iPS cells derived 
from individuals with different cyto-
chrome p450 enzymes would be of value 
for predicting the liver toxicity of new 
drugs. The disorder long QT syndrome 
(LQTS) is caused by mutations in genes 
involved in generating cardiac action 
potentials resulting in lethal arrhythmias. 
LQTS can also be induced by certain 
drugs in sensitive individuals. By gener-
ating beating cardiac myocytes from iPS 
cells derived from these sensitive indi-
viduals, candidate drugs could be tested 
in vitro.
Generating in vitro disease models 
using iPS cell technology will be use-
ful not only for drug screening but also 
for elucidating mechanisms of dis-
ease pathogenesis. A small fraction 
of patients with the familial form of the 
neurodegenerative disease ALS carry 
mutations in the SOD gene, and trans-
genic mice carrying the mutant human 
SOD gene can be used to study ALS 
pathogenesis. Recently, Dimos et al. 
(2008) generated iPS cells from a patient 
suffering from familial ALS and derived 
motor neurons from the iPS cells, provid-
ing an unprecedented in vitro resource 
for elucidating why motor neurons die 
in ALS patients. Park et al. (2008a) have 
generated iPS cells from patients with 
ten different diseases including Parkin-
son’s disease and juvenile diabetes, and 
Ebert et al. (2009) have done the same 
for SMA patients. An important chal-
lenge is how to recapitulate disease in 
cells derived from patient-specific iPS 
cells. In genetically inherited diseases .with high genetic penetrance and early 
onset, specific pathologies may be 
easier to model. Indeed, motor neurons 
generated from iPS cells derived from 
an SMA patient exhibit selective deficits 
compared to those generated from iPS 
cells derived from the patient’s healthy 
mother. But in many neurodegenerative 
diseases such as ALS, it takes years for 
symptoms to develop. We need to find 
ways to facilitate disease pathogenesis 
in patient-specific iPS cells and to mimic 
epigenetic changes caused by aging and 
the environment. Some kind of stimula-
tion, such as oxidative stress or UV irra-
diation, may be required.
Another important issue is that many 
diseases may be cell non-autonomous, 
that is attributable to more than one cell 
type. For example, motor neurons alone 
derived from ALS patient-specific iPS 
cells may not be able to reconstitute full 
disease pathogenesis as they may need 
to interact with glial cells (Di Giorgio et 
al., 2007). Thus, multiple cell types may 
need to be generated from patient-spe-
cific iPS cells. Alternatively, motor neu-
rons derived from ALS patient-specific 
iPS cells may need to be transplanted 
into mice to generate an effective dis-
ease model.
Predictions for the Future
The potential of iPS cell technology is 
enormous, but this technology is still in 
its infancy. To realize the full application 
of iPS cells, it will be essential to improve 
the methodologies for iPS cell genera-
tion and to precisely evaluate each clone 
and subclone of iPS cells for their safety 
and efficacy. Here, I discuss emerging 
technologies for direct reprogramming 
of somatic cells to iPS cells (Figure 2).
From 24 to Zero?
How many genes are required to make 
iPS cells? The first iPS cell lines were 
generated by cotransduction with 
viruses expressing 24 different fac-
tors (Takahashi and Yamanaka, 2006). 
Subsequent experiments narrowed the 
required factors down to four: Oct3/4, 
Sox2, Klf4, and c-Myc (Takahashi and 
Yamanaka, 2006), with Oct3/4 proving 
to be the most important. The expres-
sion of Oct3/4 is highly specific for pluri-
potent stem cells, whereas the other 
three factors are expressed in other 
cells (Sox2 in neural stem and progeni-
tor cells; Klf4 in skin, stomach, intestine, 
and skeletal muscle; c-Myc is ubiqui-
tously expressed). In addition, Oct3/4 
cannot be replaced by other Oct family 
members (Oct1 or Oct6) to generate iPS 
cells (Nakagawa et al., 2008). In con-
trast, Sox2 can be replaced by Sox1, 
Klf4 by Klf2 or Klf5, and c-Myc by N-Myc 
or L-Myc. Oct3/4 is absolutely required 
for the maintenance of ES cell pluripo-
tency (Niwa et al., 2000). Inactivation of 
Sox2 leads to ES cell differentiation, but 
the forced expression of Oct3/4 rescues 
this phenotype (Masui et al., 2007). Mice 
lacking either Klf4 or c-Myc survive to 
birth, indicating that other factors com-
pensate to maintain pluripotency. These 
findings argue that Sox2, Klf4, and 
c-Myc are not fundamentally required 
for iPS cell generation.
Kim et al. (2009) have generated iPS 
cells from adult mouse neural stem cells 
using Oct3/4 alone. They expressed 
Oct3/4 in the neural stem cells and 
obtained three iPS cell clones, with two 
clones yielding adult chimeric mice, 
albeit with a low contribution from iPS 
cells judging by the coat color. Fur-
ther studies are required to determine 
whether iPS cells can be generated from 
other mouse cells and human cells using 
Oct3/4 alone.
Virus? Plasmid? Small Molecule?
Which reprogramming method is the 
most appropriate for future clinical appli-
cation? Many groups have generated 
mouse or human iPS cells using either 
retroviruses or lentiviruses. Established 
iPS cells contain multiple viral integra-
tion sites in their genomes. During iPS 
cell generation, integrated proviruses 
are silenced and in turn the endogenous 
genes encoding the four factors are acti-
vated. The use of retroviruses or lentivi-
ruses raises safety issues for iPS cells 
generated in this way. Viral integration 
often takes place within endogenous 
genes and can result in gene activation. 
When patients with X-linked severe com-
bined immunodeficiency were treated 
with gene therapy using retroviruses, 
activation of the proto-oncogene LMO2 
resulted in leukemia (Hacein-Bey-Abina 
et al., 2003). However, in iPS cell clones, 
viral integration sites can be determined 
by inverse PCR enabling exclusion of 
clones showing dangerous retroviral 
integration. Each iPS cell clone may have up to 40 retroviral integration sites, but 
these sites could be identified efficiently 
by whole-genome sequencing high-
throughput methods.
Another possible obstacle to using 
retroviruses and lentiviruses is trans-
gene reactivation. Indeed, reactivation 
of c-Myc carried by a retrovirus resulted 
in tumor formation in ~50% of chimeric 
mice generated from iPS cells (Okita et 
al., 2007). Although iPS cells can be gen-
erated without c-Myc (Nakagawa et al., 
2008; Wernig et al., 2008), reactivation of 
the other three reprogramming factors 
also may cause tumors. Furthermore, 
the sustained expression of transgenes 
might suppress the differentiation of iPS 
cells, resulting in a higher propensity to 
produce teratomas when transplanted 
into patients.
Two groups have shown that it may 
be feasible to induce iPS cells without 
viral integration. Stadtfeld et al. (2008b) 
generated iPS cells from mouse hepa-
tocytes using adenoviruses carrying 
the four reprogramming factors. In an 
independent study, our group generated 
iPS cells from mouse embryonic fibro-
blasts using plasmids (Okita et al., 2008). 
We used 2A self-cleavage sequences 
to express Oct3/4, Sox2, and Klf4 in a 
single expression vector. The repeated 
transfection of mouse embryonic fibro-
blasts with this plasmid and another car-
rying c-Myc cDNA enabled generation of 
iPS cells. Many of these plasmid-gener-
ated iPS cells did not show integration 
into the host genome by either PCR or 
Southern blotting. More recently, iPS 
cells have been generated by genomic 
integration of the four reprogramming 
factors using plasmids (Kaji et al., 2009), 
lentiviruses (Soldner et al., 2009), or 
transposons (Woltjen et al., 2009), fol-
lowed by transgene removal using Cre-
mediated excision or re-expression of 
transposase. The efficiency of iPS cell 
generation using adenoviruses or plas-
mids is extremely low.
Another way to avoid viral integration 
is to generate iPS cells using chemicals 
or small molecules. Several groups have 
already identified chemicals that can 
replace one or two reprogramming fac-
tors during iPS cell generation (Huangfu 
et al., 2008; Shi et al., 2008). Considering 
the essential roles of Oct3/4, chemicals 
that robustly activate the endogenous COct3/4 gene may be able to generate 
iPS cells. Even if iPS cells do not exhibit 
transgene integration, they may have 
other genetic alterations, such as inte-
gration of small plasmid fragments or 
chemically induced mutations. It may 
be necessary to sequence the whole 
genome of iPS cell clones using the 
next generation sequencing technolo-
gies in order to detect these genetic 
alterations.
Fibroblasts? Hepatocytes? Blood 
Cells?
Which somatic cells are the best sources 
for iPS cells destined for clinical and 
pharmaceutical applications? In addi-
tion to fibroblasts, mouse iPS cells have 
been generated from bone marrow cells 
(Takahashi and Yamanaka, 2006), hepa-
tocytes and gastric epithelial cells (Aoi 
et al., 2008), pancreatic cells (Stadtfeld 
et al., 2008a), neural stem cells (Kim et 
al., 2008; Silva et al., 2008), and B lym-
phocytes (Hanna et al., 2008). Human 
iPS cells have been generated from skin 
fibroblasts, keratinocytes (Aasen et al., 
2008), and blood progenitor cells (Loh et 
al., 2009).
The first issue is to obtain somatic 
cells from donors simply and safely. 
Cells such as leukocytes meet this cri-
terion as do epithelial cells from the oral 
mucosa. Generation of iPS cells from the 
follicle cells of a single human hair also 
has been reported (Aasen et al., 2008). 
Skin fibroblasts and keratinocytes can be 
obtained using a small skin biopsy, gas-
tric epithelial cells by endoscopic biopsy, 
and bone marrow cells and hepatocytes 
by needle biopsy. Tissue can also be 
obtained when patients undergo sur-
gery. Other sources include cell banks 
such as those for cord blood; it would 
be extremely useful if iPS cells could be 
generated from cord blood cells.
The second issue is that iPS cells 
from different origins may have differ-
ent propensities to differentiate. Certain 
cell types may be better for complete 
reprogramming with a reduced risk of 
teratoma formation. It may be easier to 
generate pancreatic-β cells and hepato-
cytes from iPS cells derived from somatic 
cells of endodermal origin such as gas-
tric epithelial cells. Notably, iPS cells 
derived from mouse hepatocytes (Aoi et 
al., 2008) or human keratinocytes (Aasen 
et al., 2008) have fewer retroviral integra-ell 137, April 3, 2009 ©2009 Elsevier Inc. 15
tion sites than do iPS cells derived from 
fibroblasts. These cells may be a better 
source for iPS cell generation; iPS cells 
also have been generated from mouse 
hepatocytes using adenoviral vectors 
(Stadtfeld et al., 2008b).
Induced Somatic Stem/Progenitor 
Cells? 
The ability to form teratomas is a charac-
teristic of pluripotent stem cells, includ-
ing ES cells and iPS cells. Somatic stem 
cells, such as hematopoietic stem cells 
and mesenchymal stem cells, do not 
form teratomas. Therefore, if we could 
generate somatic stem or progenitor 
cells directly from fibroblasts or other 
types of somatic cells, it might alleviate 
the necessity of obtaining iPS cells and 
hence would remove the risk of teratoma 
formation. Given that only a few factors 
are required to make iPS cells, perhaps 
a few transcription factors and other pro-
teins are all that are needed to generate 
somatic stem or progenitor cells. Alter-
natively, direct transdifferentiation of 
one adult somatic cell into another may 
be the ultimate goal. Zhou et al. (2008) 
identified three transcription factors 
(Ngn3, Pdx1, and Mafa) that reprogram 
differentiated adult mouse pancreatic 
exocrine cells into cells that resemble 
pancreatic-β cells in morphology, size, 
gene expression, and insulin secretion. 
These new technologies may replace 
current technologies for generating iPS 
cells and ES cells for use in regenerative 
medicine.
Evaluation
It is extremely important that the same 
criteria be shared among different labo-
ratories to evaluate technologies for iPS 
cell generation. The standard criterion to 
evaluate mouse ES cells is their ability 
to generate germline-competent adult 
mouse chimeras. Teratoma formation is 
considered the minimum requirement for 
evaluating human ES cell lines. Whether 
the same criteria should be used to eval-
uate iPS cells is controversial (Daley et 
al., 2009; Ellis et al., 2009). I would like to 
propose that two groups of technologies 
should be distinguished and evaluated 
using distinct criteria. With one group, 
the purpose is to recapitulate complete 
reprogramming of nuclear information, 
which is achieved by nuclear transfer or 16 Cell 137, April 3, 2009 ©2009 Elsevier Incfusion with ES cells. In this case, result-
ing mouse stem cells should be compe-
tent for chimera formation and germline 
transmission. Human stem cells should 
form teratomas, like human ES cells. 
However, we note that teratoma forma-
tion does not guarantee full reprogram-
ming as many mouse ES cell-like cell 
lines form teratomas but fail to produce 
germline chimeras. Currently, it is dif-
ficult to prove full reprogramming in 
human cells.
With the second group of technolo-
gies, the purpose is to produce useful 
stem or progenitor cells for drug discov-
ery, toxicology, and regenerative medi-
cine and to create disease models. In 
this case, the resulting cells do not have 
to be germline competent or even tera-
toma competent, as long as they can 
self-renew and produce useful progeny. 
Indeed, cells without the ability to form 
teratomas might be more useful and 
safer for regenerative medicine.
In both cases, new technologies should 
be evaluated by chimera formation and 
germline transmission (mouse) and tera-
toma formation (mouse and human) in 
addition to other standard criteria such 
as morphology, marker expression, gene 
expression, and in vitro differentiation. 
Scientists then have to clarify whether 
their new technology induces full repro-
gramming or partial reprogramming that 
yields useful stem or progenitor cells. Ini-
tial publications reporting full reprogram-
ming should be followed up by long-term 
observations of chimeric mice and their 
progeny to evaluate the safety of the 
technology. For partial reprogramming, 
examining germline transmission and 
teratoma formation may not be an abso-
lute requirement for initial publication but 
should be examined and reported to the 
community later as a sound scientific 
practice.
A key advantage of iPS cell technology 
is its simplicity: iPS cells can be gener-
ated in any laboratory using standard 
techniques and equipment. Each experi-
ment generates many iPS cell clones 
(an advantage over many other stem 
cell technologies), although the best iPS 
cell clones need to be selected from 
numerous candidates. In mice, reporter 
systems using ES cell-specific genes, 
such as Oct3/4 and Nanog, are useful for 
detecting germline-competent clones .(Meissner et al., 2007; Okita et al., 2007; 
Wernig et al., 2007); similar reporter sys-
tems may be needed for human cells. 
However, we do see a substantial differ-
ence even among clones selected using 
reporter systems. To realize the full appli-
cation of iPS cells we have to develop 
technologies that enable selection of the 
best clones.
When evaluating cells, we should 
realize that iPS cells are not uniform 
even within each clone. After retroviral 
integration, it takes more than 10 days 
before full reprogramming is achieved. A 
single transduced progenitor cell under-
goes multiple cell divisions during this 
initial period, and progeny cells may be 
different in their reprogramming status 
despite the same origin. Even if only a few 
cells are aberrantly reprogrammed and 
refractory to differentiation, those cells 
could result in immature teratoma for-
mation after transplantation to patients. 
It will be essential to develop methods 
to detect and remove such aberrantly 
reprogrammed cell populations within 
good clones.
Conclusions
Over the next few years, I believe we 
will see many advances in the realiza-
tion of in vitro applications of iPS cell 
technology. But we cannot be too care-
ful when it comes to applying iPS cell 
technology to regenerative medicine. 
Any iPS cells generated by any method 
from any cell source will have to go 
through vigorous examination to con-
firm their safety prior to clinical appli-
cation. The general view is that the 
fewer reprogramming factors used, the 
safer will be the resulting iPS cells. But 
is it that simple? It may be difficult to 
achieve complete reprogramming with 
a smaller number of factors. Indeed, 
aberrant reprogramming may render 
iPS cells refractory to differentiation 
and thereby increase the risk of imma-
ture teratoma formation after directed 
differentiation and transplantation into 
patients. Even if only a small portion of 
cells within each iPS cell clone shows 
impaired differentiation, then those 
cells might be sufficient to produce 
immature teratomas. We must estab-
lish ways to precisely evaluate each 
iPS cell clone and to select appropriate 
subclones prior to clinical application.
Despite these challenges, the poten-
tial of these new pluripotent stem cells 
remains enormous. The biggest chal-
lenge, direct reprogramming by defined 
factors, has been resolved. The remain-
ing challenges are basically technical 
issues, which I believe will be resolved 
in the near future. I sincerely hope that 
iPS cell technology will lead to a better 
understanding of nuclear reprogram-
ming and that it will provide great ben-
efits to many patients.
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